Burst Diagnostics
Handheld, power-free, point-of-care rapid antigen diagnostics.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor | €0.0 | round | |
| investor investor | €0.0 | round | |
| investor | €0.0 | round | |
* | N/A | $2.4m | Early VC |
| Total Funding | 000k | ||
Related Content
Burst Diagnostics, founded in 2020 by Dr. Charles Henry, is a medical technology company based in Fort Collins, Colorado. Dr. Henry, a professor at Colorado State University with over 220 publications and 9 patents, serves as the CEO. The company is developing a platform for at-home and point-of-care (POC) diagnostic testing designed to provide the accuracy of laboratory tests in a handheld, power-free device.
The core of the company's offering is its proprietary Capillary-Driven Immunoassay (CaDI) technology. This platform miniaturizes and automates the steps of a traditional laboratory ELISA, including washing and signal amplification, into a simple microfluidic cartridge that resembles a standard lateral flow test. The technology aims to address the sensitivity gap between lab-run molecular tests and current at-home antigen tests, providing results in as little as 10 minutes. The initial development focus was on a test for SARS-CoV-2, with plans to expand to other infectious diseases like strep throat.
Burst Diagnostics operates on a business-to-business model, offering co-development, licensing, and OEM manufacturing services for partners who want to integrate the CaDI platform into their own branded diagnostic products. The company provides custom assay development compatible with various sample types, including saliva, blood, and urine, and supports multiple detection methods like chemiluminescent and colorimetric readouts. To date, the company has raised $2.44 million in funding over four rounds, including investments from Innosphere Ventures, Zymo Research, and a grant from the National Institutes of Health (NIH).
Keywords: point-of-care diagnostics, rapid antigen testing, immunoassay platform, microfluidic cartridge, handheld medical device, at-home testing, diagnostic technology, capillary-driven immunoassay, infectious disease testing, medtech, diagnostics manufacturing, ELISA, molecular diagnostics, medical diagnostics, assay development, point-of-need testing, chemiluminescence, laboratory automation, pathogen detection, OEM diagnostics